The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.

@article{Podtcheko2003TheST,
  title={The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.},
  author={Alexei Podtcheko and Akira Ohtsuru and Satoshi Tsuda and Hirouki Namba and Vladimir Saenko and Masahiro Nakashima and Norisato Mitsutake and Shigeru Kanda and Junichi Kurebayashi and Shunichi Yamashita},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2003},
  volume={88 4},
  pages={1889-96}
}
To establish a molecular targeting therapy for anaplastic thyroid carcinomas, we studied the effect of the specific tyrosine kinase inhibitor, STI571, on anaplastic thyroid cancer cell lines highly expressing c-ABL ARO (mutated p53) and FRO (undetectable p53). These lines showed marked inhibition of cell growth after treatment with STI571. In contrast, the growth of papillary thyroid cancer cell lines that harbor wild-type p53 and have low levels of c-ABL was not affected by STI571. Fluorescent… CONTINUE READING